Tabernanthalog Reduces Motivation for Heroin and Alcohol in a Polydrug Use Model.
Psychedelic medicine (New Rochelle, N.Y.) June 1, 2023 Jasper A Heinsbroek, Giuseppe Giannotti, Joel Bonilla et al. 26 citations
The potential use of psychedelic drugs as therapeutics for neuropsychiatric disorders has been limited by their hallucinogenic properties. To overcome this limitation, we developed and characterized tabernanthalog (TBG), a novel analogue of the indole alkaloids ibogaine and 5-methoxy-N,N-dimethyltryptamine with reduced cardiac arrhythmogenic risk and a lack of classical psychedelic...